Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

Journal:
The Lancet Oncology
Published:
DOI:
10.1016/s1470-2045(25)00379-1
Affiliations:
26
Authors:
29
Go to article
Institutions Authors Share
Leiden University Medical Center (LUMC), Netherlands
7.000000
 0.24
Institute Gustave-Roussy (IGR), France
2.000000
 0.07
Peter MacCallum Cancer Centre (Peter Mac), Australia
2.000000
 0.07
The Clatterbridge Cancer Centre NHS Foundation Trust, United Kingdom (UK)
1.000000
 0.03
Netherlands Comprehensive Cancer Organisation (IKNL), Netherlands
1.000000
 0.03
University of Sherbrooke (USherbrooke), Canada
1.000000
 0.03
University Medical Center Utrecht (UMC Utrecht), Netherlands
1.000000
 0.03
Hospital of the University of Montreal (CHUM), Canada
1.000000
 0.03
Radboud University Medical Centre (Radboudumc), RU, Netherlands
1.000000
 0.03
University Medical Center Groningen (UMCG), RUG, Netherlands
1.000000
 0.03
Princess Margaret Cancer Centre, U of T, Canada
1.000000
 0.03
ASST Lecco, Italy
1.000000
 0.03
Molecular Predictors and New Targets in Oncology, France
1.000000
 0.03
The University of Manchester (UoM), United Kingdom (UK)
1.000000
 0.03
Sant'Anna Hospital, Italy
1.000000
 0.03
San Gerardo Hospital, Italy
1.000000
 0.03
Barts Health NHS Trust, United Kingdom (UK)
1.000000
 0.03
University College Hospital (UCH), United Kingdom (UK)
1.000000
 0.03
MAASTRO Clinic, Netherlands
1.000000
 0.03
UCL, United Kingdom (UK)
1.000000
 0.03
Liverpool Cancer Therapy Centre, Australia
1.000000
 0.03
Interested in Oncology and Carcinogenesis?